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Abstract:  Cystic fibrosis (CF) is a chronic autosomic recessive syndrome, caused by 
mutations in the CF Transmembrane Conductance Regulator (CFTR) gene, a chloride 
channel expressed on the apical side of the airway epithelial cells. The lack of CFTR 
activity brings a dysregulated exchange of ions and water through the airway epithelium, 
one of the main aspects of CF lung disease pathophysiology. Lentiviral (LV) vectors, of the 
Retroviridae family, show interesting properties for CF gene therapy, since they integrate 
into the host genome and allow long-lasting gene expression. Proof-of-principle that LV 
vectors can transduce the airway epithelium and correct the basic electrophysiological defect 
in CF mice has been given. Initial data also demonstrate that LV vectors can be repeatedly 
administered to the lung and do not give rise to a gross inflammatory process, although they 
can elicit a T cell-mediated response to the transgene. Future studies will clarify the efficacy 
and safety profile of LV vectors in new complex animal models with CF, such as ferrets and 
pigs. 
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1. Introduction 
Cystic fibrosis (CF), the most common lethal hereditary disease among Caucasians, with a 
prevalence of approximately one in 3500 newborns, is characterized by chronic lung infections and 
inflammation that results in life expectancy being reduced, although treatment advances over the past 
several decades have raised the median predicted survival age from mid-teens in the 1970s to more 
than 36 years old today [1].  
The CF gene is located on the long arm of chromosome 7 [2] and, based on the prediction of the 
amino acid sequence of the encoded protein, it was termed CFTR (cystic fibrosis transmembrane 
conductance regulator). A whole codon deletion, resulting in the loss of a phenylalanine residue at 
amino acid position 508 (F508del) in the protein is the commonest mutation, accounting for 50-90% of 
CF patients [3]. The CFTR amino acid sequence contained 12 domains previously recognized as 
membrane-spanning sequences, and in vitro gene transfer experiments demonstrated restoration of 
chloride channel function in cystic fibrosis pancreatic cells [4]. Further work using purified CFTR 
protein in phospholipid vesicles confirmed that the protein functions as a cAMP-dependent chloride 
channel [5]. 
Lung disease in CF patients reflects chronic infection of the conducting airways with a surprisingly 
low number of  bacterial species. Staphylococcus aureus and Haemophilus influenzae are early 
colonizers, whereas Pseudomonas aeruginosa and Burkholderia cepacia complex (Bcc) often occur 
later, resulting in progressive loss of lung function and premature death. Several hypotheses link 
mutations in CFTR to development of lung disease in CF, whose hallmarks are bacterial infection with 
opportunistic pathogens and a vicious neutrophil-dominated chronic inflammatory response [6-9]. 
Current available data support  the “low volume” hypothesis which postulates that, due to absent 
chloride transport and increased sodium absorption, the height of the airway surface liquid (ASL) is 
reduced, leading to impaired mucociliary clearance [10]. Reduced mucociliary clearance leads to 
formation of thickened dehydrated mucus, which provides an ideal environment for bacterial growth, 
leading to chronic inflammation and ultimately organ failure in the CF lung. Normal CFTR is partly 
responsible for maintaining this airway surface liquid volume by means of chloride secretion and 
down-regulation of the ENaC (epithelial Na+ channel) [11]. In vitro models of polarized human cystic 
fibrosis bronchial epithelial cells demonstrate an isotonic reduction in the volume of airway surface 
liquid, and consequently impaired movement of the overlying mucus [10]. The importance of CFTR’s 
regulation of ENaC has been strengthened further by recent data demonstrating that overexpression of 
ENaC in a mouse model results in many of the key features of cystic fibrosis lung disease   
(e.g., reduction in airway surface liquid, reduced muco-ciliary clearance and increased mucus plugging 
of the lungs) without any direct impairment of CFTR function [12]. 
2. Gene therapy of CF lung disease 
Cystic fibrosis should be an ideal candidate for gene therapy, for four main reasons: (1) it is a single 
gene defect; (2) it is a recessive condition, with heterozygotes being phenotypically normal 
(suggesting gene dosage effects are not critical); (3) the main pathology is in the lung, which is 
accessible for treatment; and (4) it is a progressive disease with a virtually normal phenotype at birth, 
offering a therapeutic window. Viruses 2010, 2                                      
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In vitro and in vivo studies have suggested that only 5–10% of normal CFTR function is required to 
reverse the chloride channel defect [13-15], although it is not clear whether this has to be achieved in 
the majority of the airway epithelial cells, or whether a minority of cells expressing much higher levels 
would suffice. However, in vitro and in vivo studies suggest that nearly every cell in the sample must 
be corrected with CFTR to reverse the excess activity of ENaC [13,16,17]. These findings would 
imply that gene therapy of CF lung disease should achieve the correction of approximately every cell 
in the airway epithelium. 
Table 1. Comparison among viral vectors for CF gene therapy. 
Vector  Packaging 
Capacity 
Integration  Persistence 
of 
Expression 
Pro-inflammatory/ 
Immunogenicity 
Biosafety and 
efficiency 
studies on 
animal models 
Efficacy 
studies on 
animal 
models 
(with CFTR 
transgene) 
Clinical 
Trials 
for 
CF 
 
Adenovirus 
 
 
 
8 kb 
 
No 
 
No 
 
High 
 
Yes 
 
Yes 
 
Yes 
Adeno-
associated 
virus 
 
5 kb 
Both episomal 
and integrated 
gene expression 
 
Yes 
 
 
Low 
 
Yes 
 
Yes 
 
Yes 
 
Lentivirus 
 
8 kb 
 
Yes 
 
Yes 
 
Low 
 
Yes 
 
Yes 
 
No 
 
In clinical trials to date, two main vector systems have been harnessed to deliver the CFTR cDNA 
with appropriate promoter into host cells (for reviews, see [18-20]). First, viral vectors with the CFTR 
cDNA incorporated into the viral genome exploit the efficiency of viruses to enter host cells and 
achieve relatively high levels of gene expression. Secondly, cationic liposomes complexed with 
plasmid DNA encoding CFTR enhance the transport of the DNA into host cells. Although cationic 
liposomes seem to generate a lower immune response than current viral vector systems, the levels of 
CFTR expression using this delivery system have been relatively poor. 
The ideal vector system would have the following characteristics: (1) an adequate carrying 
capacity; (2) to be undetectable by the immune system; (3) to be non inflammatory; (4) to be safe to 
the patients with pre-existing lung inflammation; (5) to have an efficiency sufficient to correct the 
cystic fibrosis phenotype; and (6) to have long duration of expression and/or the ability to be safely re-
administered. Furthermore, to provide therapeutic benefit in vivo, the delivery of CFTR gene therapy 
must be extremely efficient to overcome the physical barriers such as thick tenacious mucus and 
pulmonary surfactant, as well as the logistical difficulties resulting from many viral receptors which 
are expressed on the basolateral membrane of bronchial epithelial cells. Much of the morbidity and Viruses 2010, 2                                      
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mortality seen in cystic fibrosis patients is related to pre-existing pulmonary inflammation; 
consequently, it is important that any vector system does not cause further inflammation. Table 1 
summarizes the characteristics of viral vectors used in CF gene therapy to date [21-23]. 
3. Lentiviral vectors 
Many viral vector systems have been developed for gene therapy applications, but most of these 
vectors are non-integrating, which limits their usefulness for transgenesis. The best characterized 
integrating viral vectors originate from the Retroviridae family, because of their intrinsic ability to 
integrate into genomic DNA. However, oncoretroviral vectors have shown limited success because of 
the requirement of cell replication for integration. Lentiviral vectors (LV) have overcome these 
limitations showing the ability to transduce nondividing cells and provide a more efficient transgene 
expression if compared with oncoretroviral vectors. Higher efficiency of LV vectors is likely due to 
the stability of transcripts derived from the lentiviral provirus because of the strong 3’ poly(A) signal 
that causes an increased cytoplasmic accumulation of the RNA of the transgene [24]. Naldini et al. 
were the first to demostrate that a LV vector derived from human immunodeficiency virus type 1 
(HIV-1) could provide efficient in vivo delivery, stable integration and long-term expression of 
transgenes into non-mitotic cells such as neurons [25,26].  
Although various lentiviruses from different species (human, simian, equine, ovine, bovine, feline, 
caprine) have been used to generate gene transfer vectors (reviewed in [27]) only HIV-1 and feline 
immunodeficiency virus (FIV) have been considered in the context of airway epithelium and cystic 
fibrosis gene therapy. Lentiviruses, such as HIV-1, have a diploid genome with two copies of single-
stranded plus RNA and a nucleocapsid constituted by the proteins derived from the gag gene, viral 
enzymes such as a protease derived from the pro gene, Rnase H, reverse transcriptase and integrase 
derived from the pol gene. The virion is enveloped by the host cell membrane containing the viral 
protein derived from the env gene. After virus entry into the cell, reverse transcription produces viral 
double strand DNA which enter in the nucleus and integrate randomly and permanently in the host 
genome, resulting in a provirus state. In the provirus, the lentiviral genome is flanked on both sides by 
the long terminal repeats (LTR), which contain the U5, R and the U3 regions. The 5’-LTR can act like 
an RNA pol II promoter. The 3’-LTR acts to terminate transcription and promote polyadenylation. The 
LTR also has recognition sequences necessary for integration into the genome. Tat is an accessory 
viral protein which activates the 5’ LTR promoter, whereas Rev controls the amount of RNA splicing 
as well as the RNA export into the cytoplasm. At the end of cycle infection, viral genomes are 
packaged, enveloped and released from the cells. Two important cis-acting DNA elements, the central 
polypurine tract sequence (cPPT) and the postregulatory element (PRE), derived from woodchuck 
hepatitis B virus, are also included in the transfer vector to enhance the transduction efficiency and 
transcript stability. In particular, cPPT has been shown to facilitate nuclear translocation of pre-
integration complexes, and PRE acts at the post-transcriptional level, by promoting nuclear export of 
transcripts and/or by increasing the efficiency of polyadenylation of the nascent transcript [28-30]. 
Another important feature in the lentiviral transfer plasmid is a 400-bp deletion in the U3 region of the 
3’-LTR, which debilitates the 5’-LTR RNA pol II promoter activity following integration creating a 
so-called self-inactivating (SIN) vector, increasing the vector biosafety profile [31]. Viruses 2010, 2                                      
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The development of lentiviral vector system, in order to achieve a gene transfer agent, is based on 
modifications of a native lentivirus genome. Presently, the lentivirus-based gene delivery system is 
constituted by four components: 1) the packaging elements like structural proteins and enzymes 
involved in the formation of the viral particles, derived from the gag-pol genes; 2) a post-
transcriptional regulator for gag and pol expression as well as nuclear RNA export encoded by the rev 
gene; 3) the vector carrying the transgene to be transferred to the target cells; 4) an heterologous 
glycoprotein i.e., vesicular stomatitis virus glycoprotein G (VSV-G) which pseudotypes the vector in 
order to increase its tropism. All structural proteins are HIV-1-derived, except the envelope because of 
the restricted host range of the HIV-1 env glycoprotein. Association of VSV-G with viral cores 
derived from lentiviruses, results in an high titer production and in a broad tropism of the vectors. 
Finally, deletion of the coding sequences for viral gene products renders the LV gene transfer vectors 
replication incompetent and makes 6–8 kb available for the insertion of desired genes, in this case a 
large transcriptional units such as an epithelial-specific promoter expressing the CFTR gene [25]. 
Lentivirus vectors only recently made their debut in human clinical trials for hematological 
disorders, such as -thalassemia and sickle cell disease [32]. In the first reported clinical trial with LV 
vectors, an HIV-1 derived vector expressing an antisense gene against the HIV-1 envelope gene 
(termed VRX496) was transferred to autologous CD4 T cells. A single intravenous infusion of these 
gene-modified autologous T cells was well tolerated in all five patients enrolled in the clinical trial; 
self-limiting mobilization of the vector and improvement of immune function was observed in four out 
of five patients [33]. Currently there are 21 clinical trials with LV vectors referring to various diseases, 
representing 1.4% of the vectors used in gene therapy clinical trials, as reported by 
http://www.wiley.co.uk/genetherapy/clinical/. 
4. Barriers to efficient viral-mediated gene transfer to the airway epithelium  
Gene therapy of cystic fibrosis lung disease needs an efficient delivery and a persistent expression 
of the CFTR transgene into the airway epithelium. LV vectors appear to be promising vehicles for 
gene delivery into respiratory epithelial cells due to their ability to infect nondividing cells and to 
integrate into the host cell genome mediating long-term persistence of transgene expression. Various 
physical and pathological barriers, inherent also to CF lung, including mucus plugs, glycocalyx 
components and mucins at the apical surface of the epithelia, represent an obstacle for viral attachment 
to the target cells and inhibit viral transduction from the luminal face [34,35]. These hurdles, together 
with immune response to vector encoded proteins [36], limit the success of in vivo application of gene 
transfer vectors in the airway epithelium. Moreover, the expression of receptors for many commonly 
used viral vectors is more abundant on the basolateral membrane than on the apical side of the 
respiratory epithelium and they are hardly accessible because of the airway tight junctions [37-39]. 
5. Gene tranfer to the airway epithelium mediated by LV vectors 
To mimic the persistent and progressive infection typical for CF patients, the bacteria can be 
encapsulated into agar beads and injected to the mouse lung via the trachea [40]. The impact of chronic 
Pseudomonas aeruginosa infection on adenovirus-mediated gene transfer was evaluated by two 
studies [41,42], which demonstrated that efficiency of adenovirus-mediated gene transfer to the airway Viruses 2010, 2                                      
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epithelium is significantly reduced by inflammation induced by Pseudomonas. Increased adenovirus-
specific CD8 cytotoxic T cell activity was considered by the authors as one of the underlying 
mechanisms [42]. Recently, we have demonstrated that LV VSV-G vector-mediated transduction of 
the airway epithelium is not affected when administered to the lung of chronically infected mice [43]. 
Although these data refer to only one day post-injection, our findings together with those previously 
published underscore the importance of considering the influence of the disease milieu when 
evaluating modes of gene therapy for such diseases in animal models. 
Other studies have shown that the capacity of LV vectors to transduce a fully differentiated 
respiratory epithelium is lower compared with an undifferentiated one. A first generation VSV-G 
pseudotyped HIV vector was able to transduce wild type CFTR into poorly differentiated human 
bronchial xenografts and its expression corrected the chloride transport defect and reverted the 
bacterial killing activity; however gene transfer was less efficient when the epithelium was fully 
differentiated [44]. A second generation LV vector could enable efficient and long-term transduction 
of a 3D spheroid culture of fetal human airway epithelial cells derived from the fetal trachea or from 
fetal airway xenografts (a culture model of airway epithelial cells in suspension showing a polarized, 
junctional and differentiated mucociliary surface epithelium) for up to 80 days [45]. LV vector-
mediated LacZ expression in the human fetal tracheal xenograft model was observed in up to 99% of 
the surface epithelial cells and the submucosal gland cells, up to nine months after vector 
administration [46], indicating that HIV-1-derived vectors mediate long-term gene expression by 
targeting a 'progenitor cell' compartment. 
Pseudotyping the vectors with heterologous envelopes and pre-conditioning of the airway tight 
junctions are the strategies currently used to overcome the paucity of receptors for lentivirus on the 
apical surface of the respiratory epithelium and to allow the access to the basolateral compartement 
receptors (Figure 1).  
Most of the studies on HIV-1-derived lentiviral mediated gene transfer in the airway epithelium 
refer to gene delivery mediated by LV vectors pseudotyped with VSV-G which is useful not only to 
allow virus particle concentration, but also to modulate virus interaction with the host immune system 
and to broaden its host range.  
VSV-G LV vectors have been shown to be inefficient in in vivo gene transfer into a fully 
differentiated epithelium unless disruption of the epithelial barrier integrity obtained with calcium-
chelating agents like EGTA [47], inhalation exposure to sulfur dioxide [48], or modification of the 
barrier function of the airway epithelium with lysophosphatidylcholine (LPC) [49] is obtained. As a 
proof-of-principle that disruption of tight junction integrity helps LV-mediated gene transfer to a 
differentiated airway epithelium, Johnson et al. demostrated that direct in vivo delivery of VSV-G 
pseudotyped HIV-1- based vector to the nasal epithelium of rats and mice failed to mediate gene 
transfer, but injury of the epithelium with sulfur dioxide (SO2) 1-2 hours before vector delivery 
strongly enhanced transduction levels of the nasal epithelium. SO2 pre-treatment also enhanced gene 
transfer to the tracheas of rodents [48]. 
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Figure 1. VSV-G LV vectors have been shown to be inefficient in in vivo gene transfer 
into a fully differentiated epithelium unless treatment with agents that disrupt the TJ 
integrity (EGTA; LPC) exposing basolateral receptors to the vector. LPC acts also 
increasing vector residence time by reducing cilial beat (blue arrow). To overcome the 
inability of VSV-G LV to efficiently infect the airway epithelium in the absence of 
injuring agents other heterologous envelope glycoproteins than VSV-G (e.g., GP64 from 
baculovirus  A. Californica) conferred to the LV vector the ability to transduce 
differentiated airway epithelium from the apical surface. 
 
 
Calcium-chelating agents may be more useful in the context of CF lung disease, since they 
transiently disrupt tight junctions [50]. CFTR function was restored after in vitro transduction of fully 
differentiated human CF airway epithelia with a VSV-G pseudotyped FIV vector formulated with 
EGTA [47]. In the same study pre-treatment of rabbit tracheas with EGTA solution for 30-60 minutes 
prior to vector application resulted in transduction mostly of lower airways (basal cells, Clara cells, 
and alveolar type II cells). Gene transfer persisted in respiratory epithelial cells for 6 weeks.  
The attachment and entry mechanism of VSV-G pseudotyped LV vectors into the airway epithelial 
cells and subsequent infection are still unknown. We demonstrated a role of glycosaminoglycans 
(GAGs) in gene transfer mediated by a third generation VSV-G pseudotyped LV vector in an in vitro 
model of polarized airway epithelial cells. In particular, heparan sulfate, chondroitin sulfate A and B 
seem to be strongly involved in the infection of respiratory cells mediated by a VSV-G pseudotyped 
LV vector [51]. However, one hour of treatment with 12 mM EGTA significantly increased VSV-G 
LV efficiency transduction in polarized cells obtained from a CF F508del homozygous patient [51], 
indicating that not all the putative attachment receptors are expressed on the apical surface of CF 
airway epithelium.  
Other biological modifers of the membrane permeability have been actively searched [22]. LPC 
pre-treatment results in a transient disruption of tight junctions, facilitating the access of lentiviral 
vectors to the basolateral membrane [49]. Other mechanisms by which LPC might enhance gene 
transfer are by acting as a mucolytic agent and by reducing cilial beat, both of which increase vector 
residence time [52]. Pre-treatment of the epithelium with 1% LPC 1 hour prior to intranasal instillation 
of a VSV-G-LV vector expressing LacZ reporter gene in mice produced significant transgene 
expression in the nasal respiratory epithelium for at least 92 days, suggesting that transduction of Viruses 2010, 2                                      
 
 
402
airway progenitor cells had occurred. Transduction with LV expressing CFTR after LPC treatment 
achieved sustained CFTR expression and partial correction of the electrophysiological defect in the 
nose of CF mice for at least 110 days [49].  
In a recent work, a VSV-G pseudotyped LV carrying LacZ or CFTR gene was delivered in the 
nostrils of mice 1 hour after pre-treatment with 0,3 % LPC via inhalation-driven instillation. LacZ 
transgene expression lasted over 24 months and was restricted to the anterior regions of transitional 
and respiratory epithelium within the dosed nasal airway affecting primarily ciliated and nonciliated 
cells, but also a low number of secretory and basal cells. At 24 months when LacZ gene expression 
was still present, the number of cells transduced was significantly reduced compared to the initial 1 
week level. Significant correction of CFTR function, measuring nasal potential, was present at 1 and 
12 months compared to untreated mice [53]. Although these findings are consistent with an 
approximate 3-month cell turnover time originally established for murine tracheal airway [54], recent 
data suggest longer turnover times (up to 17 months) in deeper regions of the mouse lung [55].Thus, it 
is currently unclear, if prolonged expression is due to vector integration into the pulmonary stem or 
progenitor cells or due to the long life-expectancy of airway epithelial cells. 
Agents disrupting tight junction structure and disturbing membrane permeability may not be useful 
in the context of CF lung disease, since CF lungs are replenished with bacterial products and 
inflammatory mediators. To overcome the inability of VSV-G-pseudotyped lentiviral vectors to 
efficiently infect the airway epithelium in the absence of injuring agents, other heterologous envelope 
glycoproteins, such as those from the Marburg virus or the Zaire subtype Ebola virus [56,57], the 
baculovirus  Autografa californica [58] and the influenza virus [59], were used to pseudotype the 
vectors. 
HIV-1-based vectors pseudotyped with the envelope from the Zaire strain of the Ebola virus (EboZ) 
gave efficient transduction (70% of positive cells) when applied to the apical side of polarized 
epithelia [56]. Ex-vivo transduction of human trachea by EboZ-pseudotyped vector resulted in high 
levels of LacZ expression as compared to VSV-G pseudotyped vector. When the Ebo-Z pseudotyped 
virus was injected in the trachea of mice, 30% of the entire tracheal epithelium was transduced at day 
28 and 24% at day 63. Interestingly, high expression was observed in submucosal glands, while 
transduction efficiency was lower in epithelia of more distal lung (airway and alveolar) cells.  
Pseudotyping with the GP64 derived from the baculovirus A. californica conferred to a FIV 
lentiviral vector the ability to transduce differentiated human airway epithelia from the apical surface 
with higher efficiency than VSV-G LV [58]. Intranasal instillation of the vector carrying LacZ 
formulated in viscous methylcellulose carrier, which is thought to act by increasing vector residence 
time, resulted in persistent gene expression in the mouse nose, with gene expression observed one year 
post-infection. 
Kremer  et al. compared the efficiency of transduction of mice nasal airways by a VSV-G 
pseudotyped vector (carrying LacZ gene) after a pre-treatment with LPC, and the same vector 
pseudotyped with GP64 envelope without any pre-treatment. In the absence of pre-conditioning the 
GP64-pseudotyped lentiviral vector resulted significantly less efficient than the VSV-G pseudotyped 
vector after LPC treatment. The levels of transduction were similar for the two vectors when a pre-
treatment with LPC was used. The cell types transduced were essentially the same with the majority of 
cells transduced being respiratory (ciliated cells). However, while the VSV-G LV resulted in persisting Viruses 2010, 2                                      
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gene expression, transduction with the GP64 LV resulted in gene expression that decline to 
undetectable levels over six months, whether or not an LPC treatment was used. These results suggest 
that the GP64-pseudotyped LV vector, in contrast to the VSV-G-pseudotyped vector, was unable to 
transduce progenitor cells for respiratory epithelium, even when used in combination with LPC pre-
treatment [52]. 
Different results in transducing airway epithelial cells in vitro and in vivo were obtained with other 
envelope proteins, such as those from influenza virus [59], Ross River virus [60], and Jaagsiekte sheep 
retrovirus [61]. For example, McKay et al. demostrated that an HIV-1-derived LV vector pseudotyped 
with influenza virus hemagglutinin could efficiently transduce, via the apical membrane, differentiated 
cultures of human and murine airway epithelial cells, and mouse tracheal epithelium in vivo, with a 
preference for ciliated cells [59]. These vectors warrant further studies about their attachment and 
entry mechanisms. 
6. Safety of LV vectors in the lung  
Gene therapy viral vectors are known to elicit transgene- or viral protein-specific immune responses 
[62]. This issue has long been studied with adenoviral vectors, with which, transgene expression in 
vivo usually extinguishes within 2 to 3 weeks, concurrent with the development of inflammation. This 
is caused by the rapid activation of potent CD8 and CD4 T cell responses against both the viral 
antigens and the transgene. In addition, activation of B cells by viral capsid proteins, leading to the 
production of neutralizing antibodies, limits effective readministration of the vector. When 
administered to the lung, adenoviral vectors activate cytolytic transgene-specific T cells [63]. This 
drawback has hindered the development of adenovirus as a gene therapy vector for CF. A preliminary 
evaluation of safety of administration of LV vectors into airways showed that in vivo delivery of a 
HIV-1-derived vector in the tracheas of C57Bl/6 mice did not induce inflammatory infiltrates post-
infection [56], and the persistent expression in mice and rabbits suggested a potential “immune 
tolerance” in these animal models [47]. Intravenous administration of LV vectors in immunocompetent 
mice induced the proinflammatory cell-adhesion molecules ICAM-1, VCAM-1, PECAM-1 and the 
costimulatory molecule B7-2 [64] and resulted in reduced duration of expression of the transgene [65], 
whereas direct administration into the retina, liver, muscle, and brain has been associated with milder 
systemic inflammatory and immune responses [66-68].  
A GP64-pseudotyped FIV vector was also used to investigate the efficacy of repeated 
administration to the airways [69]. In particular the authors reported for the first time a successful in 
vivo re-administration of lentiviral vectors to respiratory epithelia, associated with an increase 
expression of reporter or therapeutic transgenes, without the development of innate and adaptive 
responses that represent a significant limitation to clinical applications for airway diseases for other 
virus vectors, such as adenoviruses or adenoassociated viruses. In this study, GP64-FIV was 
repeatedly delivered to murine nasal epithelia, in particular four groups of mice received 1, 3, 5 or 7 
doses of the vector carrying the luciferase transgene over the same number of consecutive days. Mice 
underwent bioluminescence imaging 1, 4, 8 and 12 weeks following the final dose demonstrating 
additive increases in transgene expression with repeat dosing, probably due both to an increase of 
percentage of cells expressing a transgene and in the number of transgene copies/cells. The levels of Viruses 2010, 2                                      
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anti-GP64 IgG were measured in sera and in bronchoalveolar lavage (BAL) fluid one week after a 
booster dose of the vector, showing low levels of anti-GP64 IgG antibodies in sera for all groups of 
mice and higher levels in BAL fluid; importantly, the levels of inactivating antibodies measured with a 
neutralizing antibody assay resulted below the limit of detection indicating that though an adaptive 
immune response is mounted against the vector, it is insufficient to block gene transfer. Although these 
results are encouraging for the expression of a therapeutic protein over the life, recently published data 
argue against this scenario. Limberis and colleagues demonstrated that transient expression of Green 
Fluorescent Protein (GFP) at day 90 in alveolar epithelium following an intratracheal injection of 
VSV-G-pseudotyped HIV-1-derived vector to the mouse lung is due to transgene- and gag-specific  
T-cell activation [70]. These results suggest that issues linked to the elicitation of an immune response 
are also associated with the application of pseudotyped LV vectors for gene therapy of pulmonary 
genetic diseases, such as CF. Specifically, it has been predicted, using computational analysis, the 
likelihood of a CFTR-specific T-cell activation following expression of the therapeutic CFTR gene in 
CF subjects with the most common mutation F508del [71]. It is thus likely that expression of the 
therapeutic CFTR in CF patients with the F508del mutation could be subject to antigen cross-
presentation or activation of quiescent CFTR-specific T cells, an issue that has been understimated in 
previous clinical studies. Indeed, Limberis and colleagues identified a dominant CD8 T cells epitope in 
the CFTR gene upon intramuscular injection of an adenovirus vector expressing human wild-type 
CFTR cDNA into CFTR KO mice [72]. 
Lineage-regulated transgene expression will be necessary for effective, long-term gene therapies for 
disorders affecting the lung. Most gene therapy clinical trials directed to respiratory epithelium to date 
have used constitutive promoters such as the promoter from the cytomegalovirus (CMV) or the 
promoter in the retroviral LTR. However, long-term animal studies have indicated that, over time, 
transgene expression can be silenced from viral promoters [73,74], or can disregulate cellular genes 
near the integration site leading to tumorigenesis [75]. Thus, lineage-specific regulation of expression 
will be beneficial for many gene therapy applications to avoid vector silencing or toxicities associated 
with unregulated transgene expression. Furthermore, lung-specific transgene expression would have 
the advantage of avoiding transgene expression in antigen presenting cells, such as dendritic cells, and 
limiting immune responses against the transgene and viral encoded genes.  
Hendrickson et al. constructed a series of lentiviral vectors with regulatory elements to obtain lung-
specific transgene expression: the surfactant protein C promoter (SPC) for alveolar epithelial type II 
cell (AECII) expression, the Clara cell 10-kDa protein (CC10) for Clara cell expression in the airway, 
and the Jaagsiekte sheep retrovirus (JSRV) promoter for expression in both cell types. Transgene 
expression from the SPC and CC10 vectors was restricted to alveolar epithelial type II and Clara cell 
lines, respectively, while expression from the JSRV vector was observed in multiple respiratory and 
non-respiratory cell types. After intratracheal delivery of lentiviral vector to mice, transgene 
expression was observed in AECII from the SPC lentiviral vector, and in Clara cells from the CC10-
promoted lentivector. Transgene expression was not detected in non-respiratory tissues after 
intravenous delivery of CC10 and SPC lentiviral vectors [76].  Viruses 2010, 2                                      
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Innate immune responses to LV vectors in the context of lung gene therapy have not been 
thoroughly investigated. Epithelial respiratory cells function as part of the innate immune responses 
and not merely only as a physical barrier. Multiple substances with pro- and anti-inflammatory as well 
as antimicrobial activities are secreted by airway epithelial cells [77-79]. Airway epithelial cells can 
sense and are activated by respiratory pathogens, including viruses [80,81]. On this line, we have 
undertaken an evaluation of the pro-inflammatory potential of LV vectors in vitro in airway epithelial 
cells. A third-generation VSV-G LV vector did not induce those pro-inflammatory signals usually 
observed in human respiratory epithelial cells exposed to classical stimuli, such as TNF-, or other 
gene transfer vectors previously studied, such as adenovirus-derived vectors, except for a mild and 
transient induction of transcription of IFN- in an epithelial tracheal cell line [82]. These results, 
although indicating “stealth” properties of LV vectors in respect with pro-inflammatory potential, 
warrants further evaluation in preclinical animal models. Confirming our results in those models, there 
would be nevertheless the undoubted necessity to cope with adaptive immune response, as shown by 
Limberis and colleagues. 
7. LV-mediated gene transfer into fetal airway epithelium  
Recent studies have explored the feasibility of LV vector-mediated gene expression in the fetal 
airway epithelium, considering the advantage of a therapeutic intervention before clinical onset and in 
the absence of a functional immune response. In vivo GFP gene transfer to fetal respiratory epithelium 
has been achieved in rabbits after direct VSV-G LV intra-tracheal or intra-amniotic administration, 
hovewer tracheal delivery was associated with high fetal mortality rate (75%) and an elevated degree 
of transgene expression in the control ipsilateral uninjected fetuses, likely due to contamination of 
fetomaternal circulation, compared with intra-amniotic administration [83].  
Injection of VSV-G LV carrying GFP reporter gene into the lung parenchima of fetuses of rhesus 
monkeys resulted in transgene expression in pulmonary vasculature and alveolar cells in term fetuses 
and three month aged pups [84]. This work also indicates that postnatal lung development and function 
were not altered after fetal intraorgan gene transfer and subsequent transgene expression prenatally and 
postnatally. 
In a recent study an HIV-based lentiviral pseudotyped vector with the baculovirus GP64 envelope 
was applied to the fetal, neonatal or adult airways. Fetal intra-amniotic administration resulted in 
transduction of approximately 14% of airway epithelial cells, including both ciliated and non-ciliated 
epithelia of the upper, mid and lower airways, with a negligible alveolar or nasal transduction. A 
significant transduction of the airway epithelium mainly in distal lung and alveoli was detected at 1 
year after application following neonatal intra-nasal administration, while in the adult the majority of 
transduction was restricted to alveoli. In contrast, VSV-G pseudotyped virus transduced only after 
adult and neonatal application and no transduction was observed after fetal administration [85]. 
Taken together, these results strongly indicate that fetal airway epithelium can be transduced by LV 
vectors and that the pseudotype can be fundamental as in the transduction of adult airway epithelium. 
The early intervention with an integrating gene transfer vector able to transduce the lung via the 
lumen, avoiding immune elimination of transgenic protein and probably increasing lung stem-cell Viruses 2010, 2                                      
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transduction to result in a persistent gene expression, while ethically complex, may be a successful 
therapeutic approach for CF. 
8. Conclusions and perspectives 
LV vectors are endowed with interesting features which make them promising agents for 
application to gene therapy of CF lung disease. However, they present some drawbacks which need to 
be addressed before they can enter into the clinic. Although the issue of attachment and entry 
mechanisms has not been studied in detail, it seems that, at least in in vitro cultures of human polarized 
airway epithelia and small conventional animal models, the apical surface of the airway epithelium 
poses a strenous barrier to efficient transduction from this side, due to the lack of apical receptors. 
Moreover, while other viral vectors have been considered in light of the extracellular barriers, such as 
the thick and dehydrathed mucus layer covering the airway epithelium, comprehensive studies on this 
aspect are still lacking. The alternative to the use of tight junction disrupting agents and membrane 
detergents, which could possibly enhance the leakage of bacterial products and inflammatory 
mediators into the submucosa and further damage the CF lung, is the pseudotyping of LV envelope 
with heterologous proteins from other viruses. This approach should be evaluated in terms of the safety 
issue, when pathogen viruses are used [57]. Another approach is to use physical methods in order to 
enhance the residence time of viral vectors onto the airway epithelium, avoiding their wash out by the 
mucociliary clearance. For example, magnetofection is a nucleic acid delivery technique to cells 
supported and site-specifically guided by the attractive forces of magnetic fields acting on viral vectors 
which are associated with magnetic nanoparticles. This field is actively investigated by us and other 
research groups [86,87]. 
Most of the data on the efficacy (i.e., the correction of the electrophysiological defect) of LV 
vectors have been collected in CF mouse models. For both anatomical and physiological reasons, mice 
do not show a respiratory syndrome that is equivalent to that found in humans [88]. To develop 
meaningful LV vectors for CF gene therapy, evaluation of LV vectors should be done on novel animal 
models for CF. Pigs and ferrets seem to be better animal models to develop protocols and vectors for 
gene therapy of CF, because they share many anatomical and physiologycal similarities with those of 
human lungs [89,90]. 
The issue of immune response to transgene- and viral genes is a caveat in the use of viral vectors for 
human gene therapy. The first indications on the elicitation of innate and adaptive responses to LV 
vectors have been produced, although this field is in its infancy. It seems that LV vectors have a low 
pro-inflammatory potential, while they can stimulate a transgene-directed T cell response. Novel 
animal models may aid also in elucidating this issue. 
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